Harvard Bioscience Inc. (HBIO) Price to Earnings Ratio

This daily price chart reflects that the value of Harvard Bioscience (HBIO) on the GURU.Markets platform is -3.90, which correlates with the firm's limited pricing power due to spending cuts by biotech startups. Harvard Bioscience generates revenue by supplying Life Sciences equipment to universities and pharmaceutical centers; however, the business faces dumping from Eastern competitors and the risk of reduced scientific subsidies.

Harvard Bioscience (HBIO) - P/E Multiple from 07/04/2022 to 11/10/2026

Analytical breakdowns for Harvard Bioscience

- price and consensus price forecast:

Stock Price Harvard Bioscience Inc.|HBIO - Price Target Chart

- market capitalization details:

Market Value Harvard Bioscience, Inc.|HBIO - Real Price to Acquire Entire Company

- book capitalization information:

Accounting Value of a Share Harvard Bioscience|HBIO - Book Capitalization|Market Capitalization to Book Value harvardbioscience.com|HBIO - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples indicators:

HBIO - Company Net Income|Future Profit Harvard Bioscience|HBIO - P/E Multiple|Projected Price to Earnings Ratio Harvard Bioscience Inc.|HBIO - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Harvard Bioscience, Inc.|HBIO - Operating profit before deduction of amortization|Earnings per share for the last four quarters Harvard Bioscience|HBIO - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months harvardbioscience.com|HBIO - Earnings growth in current year|Expected earnings per share trend next year Harvard Bioscience

General company analysis:Harvard Bioscience Inc., HBIO

The P/E ratio reflects the market value of a single share relative to the net profit per share, allowing an investor to assess the capital payback period through the lens of fundamental value. By analyzing the price-to-earnings dynamics, one can understand the extent to which the market is willing to pay a premium for the status of Harvard Bioscience (HBIO) as a benchmark manufacturer of precision equipment, whose quality is critical for the accuracy of global preclinical research.

Analysis of competing companies